


# PRODUCT INFORMATION



## Tropifexor

Item No. 25748

**CAS Registry No.:** 1383816-29-2  
**Formal Name:** 2-[(3-endo)-3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl]methoxy]-8-azabicyclo[3.2.1]oct-8-yl]-4-fluoro-6-benzothiazolecarboxylic acid  
**Synonym:** LNJ452  
**MF:** C<sub>29</sub>H<sub>25</sub>F<sub>4</sub>N<sub>3</sub>O<sub>5</sub>S  
**FW:** 603.6  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 313 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Tropifexor is supplied as a crystalline solid. A stock solution may be made by dissolving the tropifexor in the solvent of choice, which should be purged with an inert gas. Tropifexor is soluble in the organic solvent DMSO at a concentration of approximately 10 mg/ml.

### Description

Tropifexor is an agonist of farnesoid X receptors (FXR).<sup>1</sup> It enhances the interaction between the human FXR ligand binding domain and the steroid receptor coactivator 1 (SRC-1) peptide in a homogeneous time-resolved fluorescence (HTRF) coactivator interaction assay (EC<sub>50</sub> = 0.2 nM). It increases expression of the FXR target genes *BSEP* and *SHP* and decreases expression of *CPY8B1* in rat liver in a dose-dependent manner, as well as increases expression of *SHP* and *FGF15* in rat ileum. Tropifexor (0.3 mg/kg) reduces triglyceride levels by 79% in rat serum. It reduces fibrosis, inflammation, and steatosis in a mouse model of nonalcoholic steatohepatitis (NASH).<sup>2</sup>

### References

1. Tully, D.C., Rucker, P.V., Chianelli, D., *et al.* Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). *J. Med. Chem.* **60(24)**, 9960-9973 (2017).
2. Laffitte, B., Hernandez, E., Kim, Y., *et al.* THU-468 - LJN452 (tropifexor) attenuates steatohepatitis, inflammation, and fibrosis in dietary mouse models of nonalcoholic steatohepatitis. *J. Hepatol.* **68(Suppl 1)**, S341-S342 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/07/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM